Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HOB Biotech Group Corp.,Ltd (688656.SS)
CNY95.58
+3.09 (+3.34%)
CN SHH Healthcare Medical - Devices
Address
C10 Building 215123
Suzhou, CN
Suzhou, CN
CEO
John Li
Website
hobiotech.com
IPO
2021-01-13
ISIN CNE100004C37
Description
HOB Biotech Group Corp.,Ltd. is an international in vitro diagnostics firm, active in both China and various global markets. It supplies advanced diagnostic assays, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immunoassays, to laboratories and hospitals. This endeavor aims to improve the treatment and care for patients afflicted with allergies and autoimmune diseases. The company was established in 2009 and is headquartered in Suzhou, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY95.58
+3.09 (+3.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
524.2K
Beta
-0.28
Float Shares
33.63M
Free Float %
53.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.69% | -12.18% | -14.43% | -21.89% | -44.21% | -27.49% | +16.37% | +192.40% | +24.94% | +74.25% | +74.25% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
95.58
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
51.21
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-1.0% Q1'26: +1.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-36.2% Q1'26: -90.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+0.8% Q1'26: +4.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+6.2% Q1'26: +0.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.9% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.3% ★ Q1'26: +14.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.72× Q1'26: 31.86× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
221.86M
est: 215.00M (+3.2%)
|
317.71M
est: 341.00M (-6.8%)
|
320.39M
est: 429.01M (-25.3%)
|
394.41M
est: 410.00M (-3.8%)
|
402.34M
est: 503.00M (-20.0%)
|
398.40M
est: 431.00M (-7.6%)
|
478.00M
478.00M – 478.00M
+10.9% YoY
|
528.00M
528.00M – 528.00M
+10.5% YoY
|
| EBITDA |
82.39M
est: 54.38M (+51.5%)
|
120.10M
est: 86.25M (+39.2%)
|
75.50M
est: 108.51M (-30.4%)
|
92.55M
est: 103.71M (-10.8%)
|
83.22M
est: 122.26M (-31.9%)
|
63.80M
est: 104.76M (-39.1%)
|
116.19M
116.19M – 116.19M
+10.9% YoY
|
128.34M
128.34M – 128.34M
+10.5% YoY
|
| EBIT |
66.99M
est: 37.32M (+79.5%)
|
100.37M
est: 59.19M (+69.6%)
|
48.56M
est: 74.46M (-34.8%)
|
59.43M
est: 71.16M (-16.5%)
|
44.07M
est: 79.44M (-44.5%)
|
24.66M
est: 68.07M (-63.8%)
|
75.49M
75.49M – 75.49M
+10.9% YoY
|
83.38M
83.38M – 83.38M
+10.5% YoY
|
| Net Income |
56.62M
est: 56.47M (+0.3%)
|
86.19M
est: 113.58M (-24.1%)
|
41.65M
est: 125.01M (-66.7%)
|
47.33M
est: 58.38M (-18.9%)
|
36.80M
est: 63.93M (-42.4%)
|
23.20M
est: 36.08M (-35.7%)
|
46.84M
46.84M – 46.84M
+29.8% YoY
|
60.13M
60.13M – 60.13M
+28.4% YoY
|
| SGA |
66.23M
est: 74.11M (-10.6%)
|
98.73M
est: 117.54M (-16.0%)
|
117.33M
est: 147.88M (-20.7%)
|
138.85M
est: 141.32M (-1.8%)
|
159.30M
est: 154.79M (+2.9%)
|
45.33M
est: 132.64M (-65.8%)
|
147.10M
147.10M – 147.10M
+10.9% YoY
|
162.49M
162.49M – 162.49M
+10.5% YoY
|
| EPS |
1.20
est: 0.89 (+34.8%)
|
1.40
est: 1.79 (-21.8%)
|
0.66
est: 1.97 (-66.5%)
|
0.75
est: 0.92 (-18.5%)
|
0.59
est: 1.01 (-41.6%)
|
0.37
est: 0.57 (-35.1%)
|
0.74
0.74 – 0.74
+29.8% YoY
|
0.95
0.95 – 0.95
+28.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-21.56M
OE per share TTM
-0.46
Owner's Yield
-0.31%
Maintenance CapEx ratio
84.71%
Maint CapEx / Avg PPE
125.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
46.6K
Shares Outstanding
63.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aixiang Xie | Secretary | — | female |
| Chun Li Li | Accounting Supervisor | — | — |
| John Li | Chairman & GM | — | male |
| Qingxin Liu | Director & Deputy GM | — | male |
| Ruoliang Sun | Deputy General Manager | — | male |
| Shuyan Han | Chief Financial Officer | — | female |
| Xiaohua Huang | Deputy General Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688656.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
